Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
858 Therapeutics General Information
858 Therapeutics has advanced its lead asset ETX‑19477—a potent and selective PARG inhibitor—into early-stage clinical trials for patients with advanced solid tumors. The company’s pipeline includes additional small molecule programs targeting novel nodes in cancer biology such as DNA repair mechanisms, innate immunity pathways, and RNA epigenetics. Recent financing rounds support ongoing clinical development.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
San Diego, California
United States
United States
Drug Pipeline
ETX-19477
Phase 1Key Partnerships
OpenBench (collaboration on AI-driven small molecule drug discovery)
858 Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Sep 27, 2024 | $50.0M | Completed | Phase 1 |
To view 858 Therapeutics's complete valuation and funding history, request access »